

1 **Title: Structural neurodevelopment at the individual level - a life-course investigation using**
2 **ABCD, IMAGEN and UK Biobank data**

3
4 **Authors:** Runye Shi^{1†}, Shitong Xiang^{2,3†}, Tianye Jia^{2,3,4,5†}, Trevor W. Robbins^{2,3,6}, Jujiao Kang^{2,3}, Tobias
5 Banaschewski⁷, Gareth J. Barker⁸, Arun L.W. Bokde⁹, Sylvane Desrivieres¹⁰, Herta Flor^{11,12}, Antoine Grigis¹³,
6 Hugh Garavan¹⁴, Penny Gowland¹⁵, Andreas Heinz¹⁶, Rüdiger Brühl¹⁷, Jean-Luc Martinot¹⁸, Marie-Laure
7 Paillère Martinot¹⁹, Eric Artiges²⁰, Frauke Nees^{7,11,21}, Dimitri Papadopoulos Orfanos¹³, Tomáš Paus^{22,23}, Luise
8 Poustka²⁴, Sarah Hohmann⁷, Sabina Millenet⁷, Juliane H. Fröhner²⁵, Michael N. Smolka²⁵, Nilakshi Vaidya²⁶,
9 Henrik Walter¹⁶, Robert Whelan²⁷, Gunter Schumann^{5,26}, Xiaolei Lin^{1*}, Barbara J. Sahakian^{2,3,6*}, Jianfeng
10 Feng^{1,2,3,28,29*}, IMAGEN Consortium

11 **Affiliations:**

12 ¹ School of Data Science, Fudan University, Shanghai, China

13 ² Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China

14 ³ Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry
15 of Education, China

16 ⁴ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology &
17 Neuroscience, SGDP Centre, King's College London, United Kingdom, SE5 8AF

18 ⁵ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Science and Technology for
19 Brain-Inspired Intelligence (ISTBI), Fudan University, Shanghai, China

20 ⁶ Department of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge,
21 Cambridge, United Kingdom

22 ⁷ Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health,
23 Medical Faculty Mannheim, Heidelberg University, Square J5, 68159 Mannheim, Germany

24 ⁸ Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London,
25 United Kingdom

26 ⁹ Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College
27 Dublin, Dublin, Ireland

28 ¹⁰ Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology &
29 Neuroscience, SGDP Centre, King's College London, United Kingdom

30 ¹¹ Institute of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty
31 Mannheim, Heidelberg University, Square J5, Mannheim, Germany

32 ¹² Department of Psychology, School of Social Sciences, University of Mannheim, 68131 Mannheim,
33 Germany

34 ¹³ NeuroSpin, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France

35 ¹⁴ Departments of Psychiatry and Psychology, University of Vermont, 05405 Burlington, Vermont, USA

36 ¹⁵ Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham,
37 University Park, Nottingham, United Kingdom

38 ¹⁶ Department of Psychiatry and Psychotherapy CCM, Charité – Universitätsmedizin Berlin, corporate member
39 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;

40 ¹⁷ Physikalisch-Technische Bundesanstalt (PTB), Braunschweig and Berlin, Germany

41 ¹⁸ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales
42 en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; Gif-
43 sur-Yvette, France

44 ¹⁹ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales
45 & psychiatrie", University Paris-Saclay, Ecole Normale Supérieure Paris-Saclay, CNRS; Centre Borelli, Gif-
46 sur-Yvette, France; and AP-HP. Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-
47 Salpêtrière Hospital, Paris, France

48 ²⁰ Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales
49 en psychiatrie"; Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli, Gif-
50 sur-Yvette; and Psychiatry Department, EPS Barthélémy Durand, Etampes, France

51 ²¹ Institute of Medical Psychology and Medical Sociology, University Medical Center Schleswig-Holstein Kiel
52 University, Kiel, Germany

53 ²² Department of Psychiatry, Faculty of Medicine and Centre Hospitalier Universitaire Sainte-Justine,
54 University of Montreal, Montreal, Quebec, Canada

55 ²³ Departments of Psychiatry and Psychology, University of Toronto, Toronto, Ontario, Canada

56 ²⁴ Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen,
57 von-Siebold-Str. 5, 37075, Göttingen, Germany

58 ²⁵ Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany;

59 ²⁶ Centre for Population Neuroscience and Stratified Medicine (PONS), Department of Psychiatry and
60 Psychotherapy, Charité Universitätsmedizin Berlin, Germany

61 ²⁷ School of Psychology and Global Brain Health Institute, Trinity College Dublin, Ireland

62 ²⁸ MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China

63 ²⁹ Zhangjiang Fudan International Innovation Center, Shanghai, China

64

65 † These authors contributed equally to this work.

66 * Correspondence authors.

67 Xiaolei Lin (Address: School of Data Science, Fudan University, Shanghai, 200433, China. Email:

68 xiaoleilin@fudan.edu.cn)

69 or

70 Barbara Sahakian (Address: Department of Psychology and Behavioural and Clinical Neuroscience Institute,

71 University of Cambridge, Cambridge, United Kingdom. Email: bjs1001@cam.ac.uk)

72 or

73 Jianfeng Feng (Address: Institute of Science and Technology for Brain-inspired Intelligence, Fudan University,
74 Shanghai, 200433, China. Email: jianfeng64@gmail.com)

75
76
77
78
79

80 **Abstract**

81 Adolescents exhibit remarkable heterogeneity in the structural architecture of brain development.
82 However, due to the lack of large-scale longitudinal neuroimaging studies, existing research has
83 largely focused on population averages and the neurobiological basis underlying individual
84 heterogeneity remains poorly understood. Using structural magnetic resonance imaging from the
85 IMAGEN cohort (n=1,543), we show that adolescents can be clustered into three groups defined
86 by distinct developmental patterns of whole-brain gray matter volume (GMV). Genetic and
87 epigenetic determinants of group clustering and long-term impacts of neurodevelopment in mid-
88 to-late adulthood were investigated using data from the ABCD, IMAGEN and UK Biobank
89 cohorts. Group 1, characterized by continuously decreasing GMV, showed generally the best
90 neurocognitive performances during adolescence. Compared to Group 1, Group 2 exhibited a
91 slower rate of GMV decrease and worsened neurocognitive development, which was associated
92 with epigenetic changes and greater environmental burden. Further, Group 3 showed increasing
93 GMV and delayed neurocognitive development during adolescence due to a genetic variation,
94 while these disadvantages were attenuated in mid-to-late adulthood. In summary, our study
95 revealed novel clusters of adolescent structural neurodevelopment and suggested that
96 genetically-predicted delayed neurodevelopment has limited long-term effects on mental well-
97 being and socio-economic outcomes later in life. Our results could inform future research on
98 policy interventions aimed at reducing the financial and emotional burden of mental illness.

99

100

101

102 **Keywords:**

103 structural neurodevelopment; longitudinal magnetic resonance imaging; individual trajectory of
104 neurodevelopment; genetic and environmental factors of brain development;

105 **Main**

106 Adolescence is a critical and active period for brain reconstruction and maturation, with regional
107 changes of synaptic morphology, dendritic arborization, cortical cell firing and changes in
108 neurochemical receptor affinity¹⁻³. Clinical symptoms of many neuropsychiatric disorders start
109 to emerge during this period, including conduct disorder, mood disorder and schizophrenia⁴⁻⁷.
110 Structural neurodevelopment during adolescence is important for enhanced cognitive abilities
111 and mental well-being persisting into adulthood⁸⁻¹⁶. Population-based studies have shown that
112 adolescents exhibit remarkable heterogeneity in terms of structural neurodevelopment¹⁷⁻¹⁹, but
113 the neurobiological basis of the heterogeneity remains poorly understood. Most efforts have been
114 devoted to study the functional circuitry and structural composition of the brain and their
115 associations with mental health disorders at the population level^{1,20-25}. These pioneering studies
116 have leveraged large population cohorts and refined our understanding of the adolescent brain.
117 However, associations between behavioral patterns and trajectories of brain development vary at
118 the individual level and understanding the sources of variation remains imperative in the arena of
119 public health and precision medicine^{12,18,26,27}.

120
121 Large-scale longitudinal neuroimaging studies have enabled delineation of the dynamic changes
122 of individual brain morphology, by clustering adolescents according to their developmental
123 trajectories of neuroimaging-derived phenotypes. Similar approaches have yielded associations
124 between atypical brain structure and neuroanatomical variation across neuropsychiatric
125 disorders²⁸. Neuroimaging biomarkers offered tremendous versatility to determine the
126 neuropathological mechanisms of neurodegenerative and mental illnesses²⁹⁻³³, but have yet not
127 been fully utilized for neurodevelopment. Structural magnetic resonance imaging (sMRI)
128 provides non-invasive measures of imaging-derived phenotypes, among which the
129 developmental courses of gray matter volume (GMV) were shown to be strongly associated with
130 myelinogenesis and synaptic plasticity during adolescence³⁴⁻³⁸. Collectively, this raises the
131 possibility of identifying novel clusters of dynamic brain structure according to the growth
132 trajectories of whole-brain GMV architecture.

133
134 In this study, we aim to investigate the individual heterogeneity of adolescent brain development,
135 potential genetic, epigenetic and environmental factors that could contribute to the heterogeneity,

136 and possible long-term impacts of the heterogeneous brain developmental patterns on the
137 biological and social wellbeing later in life. To accomplish these goals, we employ a data-driven
138 approach to cluster adolescents into groups with distinct whole-brain GMV developmental
139 patterns using longitudinal neuroimaging data from the IMAGEN cohort that spanned the entire
140 period of adolescence and early adulthood (schematic workflow in Fig. 1a). Both genome-wide
141 and epigenome-wide association studies are conducted to dissect the genetic and epigenetic
142 changes associated with each cluster.

143

144 **Results**

145 **Developmental trajectories of whole-brain GMV during adolescence define three clusters.**

146 We began by estimating the longitudinal trajectories of GMV in 44 brain regions of interest
147 (ROIs) (34 cortical and 10 subcortical ROIs) that spanned the whole brain of each adolescent
148 across baseline (at age 14y) and two follow-up scans (at age 19y and 23y) in the IMAGEN study,
149 adjusting for intracranial volume (ICV), sex, handedness and site (Methods). Individuals showed
150 strong heterogeneity and clustering patterns in terms of baseline total GMV and GMV
151 developmental trajectories (Supplementary Fig. 1). Next, we reasoned that neurobiologically
152 meaningful clusters could be explained by the developmental patterns in a subset of ROIs.
153 Therefore, we conducted dimension reduction via principal component analysis (PCA) and
154 selected the first 15 principal components (PCs), which explained 80% of the total variation in
155 whole-brain GMV trajectories, in the clustering analysis (Supplementary Table 1). The first and
156 second PCs defined two combinations of GMV trajectories over the entire brain that were
157 significantly associated with baseline total GMV (Supplementary Fig. 2a). However, they
158 exhibited different association patterns with items of the Cambridge Gambling Task, where PC1
159 was significantly associated with delay aversion ($r = 0.07$, $P_{adj} = 0.30$) and risk adjustment ($r = -$
160 0.08 , $P_{adj} = 0.020$), and PC2 was significantly associated with deliberation time ($r = 0.1$, $P_{adj} =$
161 0.003), overall betting (proportion bet) ($r = 0.07$, $P_{adj} = 0.014$) and risk-taking ($r = 0.08$, $P_{adj} =$
162 0.008) (Supplementary Fig. 2b). These PCs were then used in the multivariate clustering to
163 identify groups of adolescents with distinct neurodevelopmental patterns.

164

165 Among 1,543 adolescents with at least two sMRI scans, our analyses identified three clusters of
166 structural neurodevelopment ($P_{\text{permutation}} < 0.001$) (Supplementary Fig. 3). Group 1 consisted of

167 711 (46.1%) adolescents, had high baseline total GMV and continuously decreasing GMV at
168 follow-ups, which was consistent with the population GMV developmental trend²⁸. Group 2
169 included 765 (49.6%) adolescents and compared to Group 1, they had lower baseline total GMV,
170 lower peak GMV, and slower rate of GMV decrease. In addition, adolescents in Group 2 are
171 more likely to be older ($Diff = 0.11y$, $P < 0.001$) and be males ($Diff = 9.5\%$, $P < 0.001$), have
172 lower parental education ($P = 0.020$ for maternal education; $P = 0.003$ for paternal education) and
173 lower WISCIV full score at age 14 ($Diff = -1.76$, $P = 0.011$). The remaining 67 (4.3%) belonged
174 to Group 3, among whom we observed the lowest baseline total GMV and surprisingly
175 increasing GMV at follow-ups, which was opposite to the population developmental trend (Fig.
176 1b, Supplementary Fig. 4-6). Compared to Group 1, Adolescents in Group 3 are more likely to
177 have lower parental education ($P = 0.015$ for maternal education; $P = 0.010$ for paternal
178 education) and lower WISCIV full score at age 14 ($Diff = -9.22$, $P < 0.001$). The full
179 demographic and baseline characteristics for each group were provided in Supplementary Table
180 2. Since we aim to investigate group-specific brain developmental patterns in late childhood, we
181 further estimated the age-specific GMV growth rate in each ROI from age 5y to 25y in each
182 group (Methods) using population neurodevelopmental curve as a reference. Consistently we
183 observed continuously decreasing GMV in Group 1 and Group 2 (with slower rate of GMV
184 decrease in Group 2), and increasing GMV in Group 3 for most ROIs (Fig. 1c), indicating
185 delayed neurodevelopment and brain maturation in Group 3 compared to the other groups.

186
187 To understand the neurobiological basis of group heterogeneity, we next tested for differences in
188 whole-brain GMV development among these groups. We observed common delayed GMV
189 development in ROIs spanning the inferior temporal, middle temporal, lateral orbitofrontal,
190 precentral and superior frontal areas in Group 3 (relative to Groups 1/2) (Fig. 1d top and
191 Supplementary Table 3). Group 2 showed lower peak GMV and slower rate of GMV decrease in
192 ROIs spanning superior frontal, caudal middle frontal, rostral middle frontal, precentral and
193 inferior parietal areas (relative to Group 1) (Fig. 1d bottom and Supplementary Table 3). These
194 are all among the last areas in the brain to mature and had been implicated to play a key role in
195 executive functions. This led us to ask whether variations in structural neurodevelopment could
196 predict the developmental trajectories of neurocognition and risk of neuropsychiatric disorders in
197 these groups.

198

199 **Structural neurodevelopment predicts neurocognition and risk factors for neuropsychiatric**
200 **disorders.**

201 To investigate the association between neurodevelopment and executive functions, we tested for
202 differences of neurocognitive performance among these groups at baseline and at the last follow-
203 up. Full results of these comparisons were provided in Supplementary Table 4. We found that
204 compared to Group 1, Group 3 with delayed neurodevelopment showed worse neurocognitive
205 performance (Spatial Working Memory, Cambridge Gambling Task (CGT) and Stop Signal Task
206 (SST)) at baseline, but most of these items improved over time with brain maturation and
207 became statistically equivalent at the last follow-up (Fig. 2a and Supplementary Fig. 7a). This
208 can be predicted by the structural architecture of GMV development in Group 3, where
209 increasing GMV in the top discriminating ROIs showed positive correlation with improvements
210 of neurocognition (Supplementary Fig. 8 and Supplementary Table 5). In contrast, Group 2 with
211 slower rate of GMV decrease showed worsened neurocognitive performance (CGT and SST) at
212 the last follow-up relative to baseline (Fig. 2a and Supplementary Fig. 7b), which could be
213 predicted by the negative correlations between the GMV developmental trajectories in the top
214 discriminating ROIs and neurocognition (Supplementary Fig. 8 and Supplementary Table 6).

215

216 The delayed brain and neurocognitive development in Group 3 led us to ask whether these
217 adolescents had increased risk for neuropsychiatric disorders. Consistent with the improvements
218 of neurocognition, we observed decreased attention-deficit/hyperactivity disorder (ADHD)
219 symptoms, but increased depression symptoms in Group 3 (Fig. 2b and Supplementary Table 4).
220 This indicated that although neurocognitive abilities in Group 3 exhibited pronounced
221 improvement during adolescence, this was not necessarily the case for mental disorder symptoms.
222 Furthermore, consistent with their worsened neurocognitive performances, we observed
223 increased depression symptoms in Group 2 at the last follow-up compared to baseline, (Fig. 2b
224 and Supplementary Table 4). The continuously worsened neurocognition and mental health
225 problems in Group 2 indicated biological, social and mental disadvantages among these
226 adolescents.

227

228 Given the slightly different patterns of GMV development for males and females²⁸, we
229 conducted the analyses stratified by sex following the same workflow. Results of group
230 clustering largely overlapped with the original analyses (Supplementary Table 7). In general, the
231 sex-stratified analyses revealed similar patterns of neurocognition and mental health symptoms
232 among three groups of adolescents. However, differences of neurocognition among these groups
233 were manifested more for risk-taking and impulsive behaviors in males, while for spatial
234 working memory in females (Supplementary Table 8). Besides, increase of the depressive
235 symptoms in Group 2 was only observed in males, and increase of the depressive symptoms in
236 Group 3 was only observed in females.

237
238 In addition, we compared the genetic liability to major neurodevelopmental disorders and related
239 traits, including ADHD, autism spectrum disorder (ASD), educational attainment (EA) and
240 intelligence (IQ), by calculating the corresponding polygenic risk scores (PRS) for each
241 adolescent. Group 3 had higher PRS for ADHD than both Group 1 ($P_{adj} = 0.007$) and Group 2
242 ($P_{adj} = 0.017$), while Group 2 was not statistically different from Group 1 ($P_{adj} = 0.42$). We did
243 not observe significant differences among the three groups in terms of the PRS of ASD, EA and
244 IQ (Supplementary Table 9). The higher genetic liability of ADHD in Group 3 led us to ask
245 whether genetic variants could explain the delayed neurodevelopment and neurocognitive
246 performances in this group.

247 248 **Genetic variation and epigenetic changes contribute to structural neurodevelopment.**

249 To better understand the genetic basis of structural neurodevelopment, we conducted genome-
250 wide association studies (GWAS) for Group 3 versus Groups 1/2 using group-reweighted GMV
251 as the proxy-phenotype among 7,662 adolescents in ABCD, since GWAS was under-powered
252 for the IMAGEN study due to limited sample size³⁹. Group-reweighted GMV was derived and
253 used as the proxy phenotype because GMV developmental patterns could not be estimated in
254 ABCD due to limited age range. This continuous phenotype represented one's tendency of being
255 in Group 3 relative to Groups 1/2, or in other words, one's propensity of having delayed brain
256 development. Specifically, we began by calculating the ROI-specific weight in discriminating
257 Group 3 (relative to Groups 1/2) in IMAGEN adjusting for potential confounders, and applying
258 these weights to corresponding ROIs in ABCD to obtain the Group3-reweighted GMV, which

259 was then used as the proxy phenotype in the Group 3 GWAS (Methods). The Group3-reweighted
260 GMV showed negative correlation with neurocognition in ABCD, indicating the validity of
261 using Group3-reweighted GMV as appropriate proxy for delayed neurodevelopment (Fig. 3a and
262 Supplementary Table 10). Similarly, Group2-reweighted GMV was calculated and used as the
263 proxy phenotype in the Group 2 GWAS.

264
265 One locus showed genome-wide significant effects in the Group 3 GWAS (Fig. 3b and
266 Supplementary Table 11). The lead single-nucleotide polymorphisms (SNP), rs9375442 ($\beta =$
267 0.52 , $P = 1.02 \times 10^{-8}$) on chromosome 6, is an intronic variant located on *CENPW* (Supplementary
268 Fig. 9). *CENPW* is a protein-coding gene involved in the packaging of telomere ends and cell
269 cycle mitotic^{40,41}, and increased *CENPW* expression in progenitors could lead to decreased
270 cortical volume and cognitive function by altering neurogenesis or increasing apoptosis⁴². Other
271 variants on these genes were reported to be associated with cortical surface area and brain
272 volume⁴³⁻⁴⁸ (Supplementary Fig. 10), general cognitive ability⁴⁹⁻⁵¹ and physical growth⁵²⁻⁵⁶.
273 Gene-based association analysis confirmed the identification of *CENPW* (Supplementary Fig.
274 11). Next, we conducted validation of the Group 3 GWAS back in IMAGEN. We began by
275 calculating the polygenic risk score for SNPs ($N_{SNP} = 4$) residing in *CENPW* (*CENPW* score) and
276 across the whole genome (PRS) that are associated with Group3-reweighted GMV for each
277 adolescent in IMAGEN, tested for the differences of PRS among these groups, and correlated the
278 PRS with neurocognition and behavioral risk factors. Consistent with the Group 3 GWAS, we
279 observed higher *CENPW* score in Group 3 relative to Groups 1/2 (Fig. 3c) and positive
280 correlations between *CENPW* score and improvement of neurocognition and conduct problems
281 (Fig. 3d). Similar results were obtained for PRS (Supplementary Fig. 12).

282
283 No genome-wide significant SNPs were identified in the Group 2 GWAS (Supplementary Fig.
284 13). However, the large overlap between the neurodevelopmental patterns and homogeneous
285 genetic liability in Group 2 with Group 1 led us to reason that the differences of neurocognitive
286 performances between Group 1 and 2 were quantitative (rather than qualitative) and might
287 subject to the effects of environmental exposure. To test this, we performed epigenome-wide
288 association studies (EWAS) in IMAGEN (Methods) using group label as the phenotype. A
289 significant hypermethylation site cg06064461 ($\beta = 25.40$, $P = 4.24 \times 10^{-8}$) (Fig. 4a) was identified

290 and mapped to *ATF2* and *MIR933* on chromosome 2. *ATF2* encodes a transcription factor of the
291 activator protein-1 family, is ubiquitously expressed in the brain and was found to be associated
292 with both neurodegeneration and neurogenesis⁵⁷⁻⁵⁹. *MIR933* shares a common promoter with
293 *ATF2* and offers neuroprotection against neurodegenerative diseases by regulating brain-derived
294 neurotrophic factor (BDNF)⁶⁰. To validate the EWAS results, we correlated the methylation of
295 cg06064461 with estimated GMV trajectory and peak GMV in Groups 1/2, and calculated the
296 mediation effects of cg06064461 methylation in the adverse environment - neurodevelopment
297 pathway. Consistent with the EWAS results, positive correlation between cg06064461
298 methylation and total GMV trajectory ($r = 0.14$, $P < 0.001$) (Fig. 4b) and negative correlation
299 between cg06064461 methylation and peak GMV ($r = -0.07$, $P = 0.020$) (Fig. 4c) were observed.
300 Although none mediation effects of cg06064461 methylation on the environment –
301 neurodevelopment pathway showed statistical significance after correcting for multiple testing
302 (Fig. 4d and Supplementary Table 12), nominal significance was observed for family affirmation,
303 where higher level of family affirmation was associated with higher peak GMV through reduced
304 cg06064461 methylation (Fig. 4e). Family affirmation was defined as behaviors that the parent
305 puts in place to support or help children in various situations or to show them approval and
306 affection and refers to parent-child relationship⁶¹. These results indicated that environmental
307 exposure could contribute to disadvantaged neurodevelopment and neurocognition by inducing
308 epigenetic changes of neurogenesis-related genes.

309
310 **Genetic variation had limited effects on the cognitive, mental health and socio-economic**
311 **outcomes in mid-to-late adulthood.**

312 Both genetic vulnerability and structural neurodevelopment are well-established to have
313 profound impact on one's physical, social and mental well-being in mid-to-late adulthood⁶²⁻⁶⁵.
314 However, the neurobiological mechanisms through which the long-term effects of genetic
315 variation could be manifested remain largely unknown. We conclude our study by testing in the
316 UK Biobank whether, and to what degree, polygenic risk for delayed neurodevelopment could
317 have impact on the long-term brain structure, cognition, social-economic outcomes and mental
318 well-being.

319

320 Motivated by the Group 3 GWAS results, we first calculated the PRS and *CENPW* score of
321 delayed neurodevelopment for each participant in UK Biobank and then correlated them with
322 outcomes of interest. Both PRS and *CENPW* score were approximately normally distributed and
323 negatively associated with total GMV among this population (Fig. 5a). Next, we inspected the
324 association of PRS and *CENPW* score with GMV in multiple brain regions in UK Biobank and
325 found that inferior temporal, fusiform, middle temporal, medial orbitofrontal and lateral
326 orbitofrontal areas were among the most correlated ROIs with PRS of delayed neurodevelopment,
327 and lateral orbitofrontal, caudal middle frontal, rostral middle frontal, insula and superior frontal
328 areas were among the most correlated ROIs with *CENPW* score (Fig. 5b and Supplementary
329 Tables 13-14). These were consistent with the worse spatial working memory among participants
330 with higher PRS of delayed neurodevelopment and *CENPW* score (Supplementary Table 15).
331 Finally, we conducted non-superiority tests of the correlation coefficients and found that
332 correlations between PRS of delayed neurodevelopment and *CENPW* score and all outcomes of
333 interest were smaller than 0.05 (Fig. 5c and Supplementary Figs. 14-15). This indicated that
334 although polygenic risks contributed to delayed neurodevelopment during adolescence, their
335 long-term influences on the cognitive, mental health and socio-economic outcomes were limited
336 once neurocognitive abilities were fully developed.

337

338 **Discussion**

339 Adolescence is a dynamic maturational period characterized by potentially suboptimal decision
340 making and an amplified risk of behavioral problems due to the immature brain and cognitive
341 abilities⁶⁶⁻⁷⁰. There is a growing consensus that adolescents have remarkably heterogeneous brain
342 developmental patterns¹⁸. Therefore, studies at the population average level may obscure the true
343 relationship between dynamic brain changes and risks for neuropsychiatric disorders. Here, we
344 developed a data-driven approach that identified three groups of adolescents with distinct whole-
345 brain neurodevelopmental patterns, and showed that these groups had associated genetic or
346 epigenetic determinants, and could predict the paths of both neurocognitive development and
347 long-term socio-economic attainments and mental well-being in mid-to-late adulthood.

348

349 Both neuroimaging and animal studies show that gray matter in higher-order brain regions
350 undergoes continuous thinning during adolescence with synaptic pruning and

351 myelination^{25,28,71,72}. Therefore, increasing gray matter during this period, especially in higher-
352 order brain regions responsible for executive functions, is indicative of delayed brain maturation.
353 Furthermore, a slower rate of gray matter thinning suggests reduced density of synapses and
354 myelination³, which would further limit the enhancement of neurocognitive function and
355 efficient information processing^{69,73,74}. These diverse growth trajectories of the adolescent brain
356 are capable of shifting both behaviors and the learning capabilities, in ways that could lead to
357 life-long impacts^{70,75-77}. Further, human brain development involves continuing and complex
358 interactions between genetic and environmental influences^{23,26,78-83}. By integrating genomic,
359 neuroimaging, behavior and health-related data from three large-scale population cohorts, we
360 confirmed that genetic variants are associated with delayed brain maturation and neurocognitive
361 development, without affecting the socio-economic and mental well-being later in life. Whereas,
362 adverse environmental exposure and the associated epigenetic changes could lead to prolonged
363 negative effects on brain development and behavioral disadvantages. Importantly, we regard the
364 differences between Group 2 and Group 1 as quantitative and subject to the magnitude of
365 cumulative adverse environmental exposure, as reflected by the large overlap in their
366 neurodevelopmental patterns and the relatively small effect sizes associated with adverse
367 environmental factors. Consolidating results from EWAS and mediation analysis, our study shed
368 light on the possible epigenetic and neurobiological mechanisms underlying potential causal
369 pathways between environmental exposure and adolescent brain development. However, it does
370 not necessarily mean that the differences between Group 3 and Group 1 could only be attributed
371 to genetic variation, or that differences between Group 2 and Group 1 was purely due to
372 environment. Future research with larger sample size and adequate statistical power are needed
373 to elucidate the potential interplay between gene and environment on structural brain
374 development.

375
376 To our knowledge, this is the first attempt to investigate longitudinal brain development at the
377 individual level and its associations with neurocognition and socio-economic outcomes
378 persisting into late adulthood. The three population cohorts involved in our analyses were
379 designed for relatively different purposes, in different populations and produced different data
380 components. Although we tried to link the neurodevelopmental patterns from IMAGEN to
381 ABCD and UK Biobank, this mapping using genetic and neuroimaging associations may subject

382 to confounding bias. For example, the bridging between IMAGEN and ABCD assumed a linear
383 change of GMV from 9 years old (baseline age for the majority participants in ABCD) to 14
384 years old (baseline age for the majority participants in IMAGEN), and homogenous population
385 composition between these two cohorts. Given the findings from existing investigations (give a
386 reference of brain chart), a linear trend of GMV from 9 to 14 years old were attainable, and in
387 order to achieve population homogeneity, we only selected participants of self-reported “White”
388 ethnicity in ABCD. In addition, both the appropriateness of using the proxy phenotype and
389 results of GWAS conducted in ABCD were successfully validated. However, validation of our
390 results, particularly the long-term impacts in mid-to-late adulthood, are required once long-term
391 follow-ups of socio-economic outcomes in these adolescents become available. Further, the
392 IMAGEN study involves healthy individuals only and our findings may have limited
393 generalizability to specific disease populations. Although these adolescents were not diagnosed
394 with specific neuropsychiatric disorders at baseline, they were likely to be present with
395 subclinical symptoms, referred to minor neurological abnormalities or dysfunction seen in the
396 absence of an obvious cause or pathology. Evidence indicated that subclinical symptoms seen in
397 normal young children were partly attributable to immaturity of the nervous system and were
398 frequently found in the clinical course of psychosis⁸⁴, schizophrenia⁸⁵ and Alzheimer’s disease⁸⁶.
399 Neuroimaging studies thus stand as a powerful tool for identifying important brain regions and
400 morphological phenotypes associated with subclinical symptoms, and for elucidating the
401 neurobiological correlates of subclinical symptoms along the course of brain development.
402 Finally, the three groups identified in this study constitute an initial attempt to solve the problem
403 of heterogeneous brain development that relies heavily on the image-derived phenotypes
404 obtained from sMRI. Further investigation using other neuroimaging modalities, or multi-modal
405 phenotypes are needed for a comprehensive understanding of this dynamic process.

406

407 **Methods**

408 **Participants** Genomic, neuroimaging, environmental exposure, behavioral and mental health
409 related data used to identify adolescent neurodevelopmental patterns were obtained from the
410 IMAGEN study. Individuals with GMV beyond 4 interquartile ranges (IQRs) in any ROI were
411 considered as outliers and were excluded from the analyses. After applying the exclusion criteria,
412 1543 adolescents with at least two structural MRI scans from 14 to 23 years old were included in

413 the analyses (Supplementary Table 16). The average number of structural MRI scans per
414 participant was 2.63, with 974 adolescents having a total of 3 scans (at 14, 19 and 23 years,
415 respectively) and 569 adolescents having a total of 2 scans (384 at 14y and 19y, 147 at 14y and
416 23y and 38 at 19y and 23y). In addition, genotyping data used in GWAS, validation of GWAS
417 and investigation of the long-term impact were obtained from ABCD, IMAGEN and UK
418 Biobank, respectively. A total of 11,760 participants aged between 9 and 11 years old from
419 ABCD were included, with the average number of structural MRI scans per adolescent 1.68.
420 Further, 502,409 participants aged between 37 and 73 years old from UK Biobank were included
421 in the long-term analyses of structural brain development. Demographics and baseline
422 characteristics of participants from the three large population cohorts were summarized in
423 Supplementary Table 17. A full description of all population cohorts used in the analyses can be
424 found in Supplementary Methods.

425

426 **Analysis of Structural MRI data**

427 **Data preprocessing** In brief, quality-controlled processed T1-weighted neuroimaging data were
428 obtained from ABCD, IMAGEN, Human Connectome Project Development (HCP-D), HCP
429 Young Adult (HCP-YA) and the Philadelphia Neurodevelopmental Cohort (PNC). Assessment
430 of regional morphometric structure were extracted by FreeSurfer v6.0 using Desikan-Killiany
431 (h.aparc) atlas for cortical regions, and ASEG atlas for subcortical regions. Quality check was
432 performed according to FreeSurfer reconstruction QC measures. Detailed description of data
433 collection and preprocessing is provided in Supplementary Methods.

434

435 **Estimation of GMV developmental trajectory** GMV trajectory in each of the 44 ROIs was
436 estimated for each adolescent using linear mixed effect regression model (*lme4* 1.1-31 package)
437 (since at most three structural MRI scans were available for each adolescent, only random slope
438 model could be robustly estimated). Empirical Bayes estimate of the random slope was extracted
439 for each adolescent. Intracranial volume (ICV), sex, handedness and imaging site were used as
440 covariates to adjust for potential confounding.

441

442 **Principal component analysis (PCA) and group clustering** Dimension reduction via PCA was
443 performed to individual GMV trajectories estimated in the 44 ROIs. The first 15 principal

444 components (Supplementary Table 1), which explained 80% of the total variation, were used in
445 the multivariate k-means clustering. The optimal number of clusters was selected based on
446 Elbow method with the constraint that each cluster contain at least 4% of the overall population.

447
448 **Permutation test** Permutation was conducted by shuffling the estimated GMV trajectory in each
449 ROI simultaneously and re-performing the dimension reduction and multivariate clustering
450 repeatedly over 1000 times. P value was calculated as the proportion of Between-cluster Sum of
451 Squares / Total Sum of Squares ratio greater than the estimated ratio in the original sample
452 across all 1000 permutations.

453
454 **Comparison of GMV trajectory among groups** Pairwise comparisons of GMV developmental
455 trajectories in each ROI among the three groups were conducted via t test. The top 5 ROIs with
456 the largest absolute t values were selected as the top distinguishing ROIs between the
457 corresponding groups (Supplementary Table 3). Cohen's ds (calculated using *effectsize* 0.8.3
458 package) for these regions were provided in Fig. 1d and Supplementary Fig. 16.

459
460 **Estimation of age and region-specific GMV development among groups** To illustrate the
461 region-specific GMV development in an extended time frame ranging from late childhood to
462 early adulthood, external neuroimaging data from several population cohorts were incorporated.
463 This includes a total of 21,826 participants comprising of 11,811 participants aged 9-14y with
464 19,587 scans in ABCD, 652 participants aged 5-22y in HCP-D, and 1,587 participants aged 8-
465 23y in PNC study. Since cubic model could not capture GMV trajectory beyond 23y and
466 quadratic model could not utilize data before 9y, we used a reference curve estimated from cross
467 sectional studies (HCP-D + PNC) in estimating the region-specific GMV developmental curve
468 over 5-25y. Distance between GMV in IMAGEN and that in the reference population in the
469 corresponding ROI was used as the dependent variable in the quadratic linear mixed effect model
470 with random intercept and slope, adjusting for ICV and site. Empirical Bayes estimates of the
471 random effects for each group were added to the population averaged estimates to yield the
472 group-specific developmental curve.

473

474 **Estimation of group-specific developmental curve of total GMV in IMAGEN** A two-stage
475 estimating procedure was adopted. Optimal model was selected among a series of polynomial
476 mixed effect models using likelihood ratio test. First, population ICV developmental curve over
477 5-23y was estimated using the above-mentioned population neuroimaging data. Quadratic linear
478 mixed effect models with random intercept at the individual and study level were fitted. To
479 estimate the developmental curve of total GMV in the reference population (ABCD + HCP +
480 PNC), cubic model adjusting for ICV was selected with random intercepts at the individual and
481 study level. To estimate the developmental curve of total GMV in the ABCD and IMAGEN
482 population, cubic model adjusting for ICV was selected with random intercept and slope at the
483 individual level. Empirical Bayes estimates of the random effects were extracted and averaged in
484 each group. Population ICV estimated in stage 1 was used to fit group-specific curves. The 5th
485 and 95th percentile of the group-specific total GMV were calculated as the 95% confidence
486 interval at each age.

487
488 **Estimation of peak total GMV in IMAGEN** To estimate the peak total GMV in the IMAGEN
489 population, 1,113 participants aged 22-38y in HCP-YA study were added to the reference
490 population. A similar two-stage estimating procedure was used and the optimal model was
491 selected based on Bayesian information criterion (BIC) and likelihood ratio test. First, population
492 developmental curve of ICV was estimated using mixed effect regression model (*nlme* 3.1-160
493 package) with random intercept and slope. Basis function involving centered age was determined
494 as the natural spline with 5 degrees of freedom. Interaction effects between age and sex, sex and
495 study were also included in the regression model. Estimated ICV at each age was retained for the
496 following analysis. Next, linear mixed effect regression model with random intercept and slope
497 was fitted for total GMV. Basis function involving centered age was determined to be B spline
498 with 12 degrees of freedom. Interaction effects between age and sex, sex and study were
499 included in the regression model. Peak total GMV was defined as the highest total GMV one can
500 achieve during brain maturation.

501
502 **Comparisons of environmental burden, neurocognition, behavior and mental disorder** To
503 assess whether environmental burden, neurocognition, behavioral risk factors and mental
504 symptoms differ by groups, we analyzed their longitudinal measurements at 14y, 16y, 19y and

505 23y in IMAGEN. Personal traits, including personality, temperament and characters, were
506 obtained from the NEO Five-Factor Inventory (NEO-FFI) and temperament and character
507 inventory (TCI-R). Environmental burden, including prenatal exposures (parental smoking,
508 maternal drinking and maternal medical problems during pregnancy), birthweight, stressful life
509 events, child trauma experiences, child's experience of family life and family stressors, were
510 obtained from Pregnancy and Birth Questionnaire (PBQ), life-events questionnaire (LEQ),
511 Childhood Trauma Questionnaire (CTQ), and Family Stress Scale and Family Life Questionnaire
512 from development well-being assessment interview (DAWBA). Neurocognitive performances
513 were obtained from Cambridge Neuropsychological Test Automated Battery (CANTAB) tests,
514 Monetary-Choice Questionnaire (KIRBY) and Stop Signal Task (SST) results. Behavioral
515 assessments, including conduct problems and substance use, were obtained from strengths and
516 difficulties questionnaire (SDQ), European school survey project on alcohol and drugs (ESPAD),
517 Fagerstrom test for nicotine dependence (FTND). Mental health conditions, including ADHD
518 and depression, were obtained from self-rated development well-being assessment interview
519 (DAWBA), where Attention-deficit/hyperactivity disorder (ADHD) score was additionally
520 calculated using parent-rated interview. A detailed description of these assessment instruments is
521 provided in Supplementary Methods. Generalized linear models adjusting for sex, handedness
522 and ICV were used for comparing these tests at baseline and at the last follow-up visit (19y for
523 Pattern recognition memory (PRM), Affective Go-No Go (AGN) and Rapid visual information
524 processing (RVP); 23y for all other tests). For child-rated ADHD and depression score, baseline
525 scores were also included as covariates. Intra-Extra Dimensional Set Shift (IED) test was only
526 available at age 23y, and parent-rated ADHD score was only available at 14y and 16y. Cohen's d
527 was calculated for each measurement after regressing out the covariates. False discovery rate
528 (FDR) was used to correct for multiple testing within scales.

529
530 **Quality control of genomic data** In this study, we performed stringent QC standards using
531 PLINK 1.90. Individuals with > 10% missing rate and single-nucleotide polymorphisms (SNPs)
532 with call rates < 95%, minor allele frequency < 0.1%, deviation from the Hardy-Weinberg
533 equilibrium with $P < 1E-10$ were excluded from the analysis. For ABCD, we only selected
534 subjects with self-reporting White ancestral origins using the public release 3.0 imputed
535 genotype data, which was imputed with the HRC reference panel⁸⁷. Considering that ABCD is

536 oversampled for siblings and twins, we randomly selected one participant within each family.
537 For IMAGEN, details about preprocessing of genomic data can be found in previous reports⁸⁸
538 and data was imputed with the HapMap3 reference panel⁸⁹. For UKB, we selected subjects that
539 were estimated to have recent British ancestry and have no more than ten putative third-degree
540 relatives in the kinship table using the sample quality control information provided by UKB. For
541 more details, please refer to the official document for genetic data of the UKB
542 (<http://www.ukbiobank.ac.uk/scientists-3/genetic-data/>). After quality control, we obtained a
543 total of 4,244,228 SNPs and 7,662 participants in ABCD, 5,966,316 SNPs and 1,982 participants
544 in IMAGEN, and 616,339 SNPs and 337,199 participants in UKB.

545
546 **Calculation of genetic liability** For each individual, polygenic risk scores (PRS) of ADHD,
547 ASD, EA and IQ were calculated based on the public GWAS summary statistics^{51,90-92} using
548 PRSice v2.3.3. For ADHD, ASD and IQ, optimal p-value thresholds were determined based on
549 the best-fit R² using parent-rated psychiatric scores for ADHD and ASD, and the total WISCIV
550 score. For EA, variants were selected using a P value threshold from 5e-08 to 1 with a step of 5e-
551 05 and an average score under each P value threshold was calculated.

552
553 **GWAS and validation** Since it was difficult to estimate individual GMV developmental
554 trajectory in ABCD with limited number of structural MRI scans per participant and limited age
555 range, we calculated the group-reweighted GMV as a proxy phenotype. There are several
556 underlying assumptions in this calculation. Firstly, it assumes that all brain regions exhibit a
557 comparable linear change from childhood to adolescence. Secondly, it assumes that the
558 participants from ABCD and IMAGEN are drawn from a homogeneous population. Once again,
559 we only included individuals in ABCD with self-report White ancestral origins. ROI-specific
560 loading contributing to group classification (Group 2 vs Group 1, Group 3 vs Group 1, Group 3
561 vs Group 2, and Group 3 vs Groups 1/2) were obtained by regressing baseline GMV in 44 ROIs
562 adjusting for age, sex, handedness and site in IMAGEN. Logistic regression model was used as
563 the classification model and top 10 ROIs with the largest loadings were used to calculate the
564 group-reweighted GMV in ABCD. Since results remained similar when comparing Group 3 vs
565 Group 1 and when comparing Group 3 vs Group 2 (Supplementary Figs. 17-18), we combined
566 Group 1 and 2 for increased statistical power, and performed the GWAS to investigate the

567 genetic variations associated with Group 3 vs Groups 1/2 (delayed brain development). GWAS
568 was conducted in the White population adjusting for sex, scanner effect and top 20 PCA
569 components using Plink 2 (Supplementary Fig. 19). To ensure the validity of group reweighted
570 phenotype, we correlated the Group-3 reweighted GMV and neurocognitive assessments (Game
571 of Dice Task, Delay Discounting Task and NIH Toolbox) in ABCD (Supplementary Methods).
572 Gene-based association analysis was conducted via MAGMA (version 1.10) using raw genomics
573 data with the same covariate adjustment. To validate the GWAS results, polygenic risk scores for
574 SNPs residing in CENPW (referred to as CENPW score) and across the whole genome (referred
575 to as PRS) were calculated. Four SNPs were obtained by clumping within 250 kb upstream and
576 downstream of CENPW (chr6:126339789-126483320) using Plink 2. PRS was calculated using
577 PRSice using the most predictive P threshold for group-reweighted baseline GMV ($r=0.06$,
578 $P=0.033$). Distribution of PRS between Group 3 vs Groups 1/2 and correlation coefficients
579 between PRS and neurocognition, behavior and mental disorder at age 14y and 23y were
580 obtained. FDR was used for multiple tests correction within scales.

581
582 **EWAS, gene-specific methylation analysis and results validation.** EWAS was performed
583 among 909 adolescents in Group 1 and Group 2 in IMAGEN. Methylation data were collected
584 using the Illumina Infinium HumanMethylation450 BeadChip. Locus-specific genome-wide
585 methylation analysis was conducted and beta values at each Autosomal CpG site between groups
586 was compared using logistic regression adjusting for sex, experimental batches (recruitment
587 center and acquisition wave), the first two principal components of methylation composition and
588 the first four principal components of estimated differential cell counts. Statistical significance
589 was set as false discovery rate (FDR) adjusted p-value < 0.05 . Next, we aimed to investigate the
590 association between CpG site and gene methylation with environmental factors of interest. We
591 conducted mediation analyses (*sem* function in the *lavaan* 0.6-12 package) and estimated the
592 total effect of childhood experiences on estimated peak GMV and the indirect effect mediated by
593 cg06064461 hypermethylation. Sex, batches effects, methylation composition components and
594 differential cell count components were included as covariates. Total, direct and indirect effect
595 and their standard deviations were estimated using 1000-iterated nonparametric bootstrap
596 approach. False discovery rate (FDR) was used to correct for multiple testing within scales.

597

598 **Long-term impacts of neurodevelopment in UK Biobank** Socio-economic, cognitive and
599 mental health outcomes were obtained at baseline visit among participants in UK Biobank.
600 Socioeconomic conditions were assessed by household income, jobs involved in physical activity
601 and Indices of Multiple Deprivation (IMD) (education, employment and income scores).
602 Cognition was assessed by fluid intelligence and the highest educational attainment. The
603 educational level was divided into four ordinal categories: (1) College or University degree; (2)
604 A levels/AS levels, NVQ or HND or HNC, other professional qualifications or equivalent; (3) O
605 levels/GCSEs, CSEs or equivalent; (4) None of the above. Mental health was assessed by
606 diagnosis of mental disorders (anxiety, depression and mania), summary score of neuroticism
607 and self-reported mental symptom appearances. A detailed description of assessment instruments
608 used in the analysis can be found in Supplementary Methods. To estimate the long-term effect of
609 delayed neurodevelopment, we calculated CENPW score and RPS according to the results of
610 Group 3 GWAS and correlated these scores with outcomes of interest after regressing out the age
611 effect at recruitment, site and gender. It should be noted that these scores only reflect a genetic
612 predicted risk for delayed brain development. Given the large age gap between participants in
613 UK Biobank and IMAGEN, it is challenging to disentangle the long-term impacts of
614 neurodevelopment from those due to potential environmental confounding in mid-to-late
615 adulthood. Therefore, this analysis only serves to explore the potential long-term influence of
616 genetically predicted delayed neurodevelopment and does not account for potential confounding
617 due to environmental factors. Similarly, we assume the homogeneity of study populations
618 between IMAGEN and UK Biobank. For PRS calculation, we used P value thresholds from 5E-
619 08 to 1 with a step of 5E-05 and calculated an average PRS score for each individual. Due to the
620 large sample size and easily-obtainable statistical significance, inferiority tests against 0.05 were
621 conducted against the null hypothesis that the absolute correlation coefficient was less than 0.05.

622

623 **Data availability**

624 Data from the ABCD study are available from a dedicated database: <https://abcdstudy.org/> by
625 application; data from the IMAGEN study are available upon application: <https://imagen2.cea.fr/>;
626 HCP data are available from: <https://www.humanconnectome.org/> by application; PNC data are
627 available from dbGaP: [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000607.v3.p2)
628 [bin/study.cgi?study_id=phs000607.v3.p2](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000607.v3.p2) by application; and UKB data are available from

629 <https://biobank.ndph.ox.ac.uk/> by application ID 19542. Summary statistics from published
630 GWAS of ADHD, ASD, EA and IQ are available at <https://atlas.ctglab.nl/>. Summary statistics of
631 the GWAS for delayed brain development in this study will be uploaded to <https://atlas.ctglab.nl/>
632 upon publication.

633

634 **Code availability**

635 Primary analyses were conducted in R v4.2.2. Linear mixed effect models were performed using
636 *lme4* 1.1-31 and *nlme* 3.1-160 R packages. Mediation analysis was performed using *lavaan* 0.6-
637 12 R package. PLINK 2.0 was used to perform GWAS and calculate *CENPW* score. MAGMA
638 v1.10 was used to perform the gene-based association analysis. PRSice v2.3.3 was used to
639 calculate the PRS. Custom code that supports the main findings of this study will be available
640 <https://github.com/abnmsry>. Additional information related to this paper are available from the
641 authors upon reasonable request.

642

643 **Reference**

644

- 645 1 Giedd, J. N. *et al.* Brain development during childhood and adolescence: a longitudinal
646 MRI study. *Nat Neurosci* **2**, 861-863, doi:10.1038/13158 (1999).
- 647 2 Lenroot, R. K. & Giedd, J. N. Brain development in children and adolescents: insights
648 from anatomical magnetic resonance imaging. *Neurosci Biobehav Rev* **30**, 718-729,
649 doi:10.1016/j.neubiorev.2006.06.001 (2006).
- 650 3 Tamnes, C. K. *et al.* Development of the Cerebral Cortex across Adolescence: A
651 Multisample Study of Inter-Related Longitudinal Changes in Cortical Volume, Surface
652 Area, and Thickness. *J Neurosci* **37**, 3402-3412, doi:10.1523/JNEUROSCI.3302-16.2017
653 (2017).
- 654 4 Paus, T., Keshavan, M. & Giedd, J. N. Why do many psychiatric disorders emerge during
655 adolescence? *Nat Rev Neurosci* **9**, 947-957, doi:10.1038/nrn2513 (2008).
- 656 5 Lee, F. S. *et al.* Adolescent mental health-Opportunity and obligation. **346**, 547-549,
657 doi:doi:10.1126/science.1260497 (2014).
- 658 6 Blakemore, S. J. Adolescence and mental health. *Lancet* **393**, 2030-2031,
659 doi:10.1016/S0140-6736(19)31013-X (2019).
- 660 7 Gunnell, D., Kidger, J. & Elvidge, H. Adolescent mental health in crisis. *BMJ* **361**, k2608,
661 doi:10.1136/bmj.k2608 (2018).
- 662 8 Haier, R. J., Jung, R. E., Yeo, R. A., Head, K. & Alkire, M. T. Structural brain variation
663 and general intelligence. *Neuroimage* **23**, 425-433,
664 doi:10.1016/j.neuroimage.2004.04.025 (2004).
- 665 9 Shaw, P. *et al.* Attention-deficit/hyperactivity disorder is characterized by a delay in
666 cortical maturation. *Proc Natl Acad Sci U S A* **104**, 19649-19654,
667 doi:10.1073/pnas.0707741104 (2007).

- 668 10 Shaw, P. *et al.* Intellectual ability and cortical development in children and adolescents.
669 *Nature* **440**, 676-679, doi:10.1038/nature04513 (2006).
- 670 11 Giedd, J. N. & Rapoport, J. L. Structural MRI of pediatric brain development: what have
671 we learned and where are we going? *Neuron* **67**, 728-734,
672 doi:10.1016/j.neuron.2010.08.040 (2010).
- 673 12 Ramsden, S. *et al.* Verbal and non-verbal intelligence changes in the teenage brain.
674 *Nature* **479**, 113-116, doi:10.1038/nature10514 (2011).
- 675 13 Schnack, H. G. *et al.* Accelerated Brain Aging in Schizophrenia: A Longitudinal Pattern
676 Recognition Study. *Am J Psychiatry* **173**, 607-616, doi:10.1176/appi.ajp.2015.15070922
677 (2016).
- 678 14 Bos, M. G. N., Peters, S., van de Kamp, F. C., Crone, E. A. & Tamnes, C. K. Emerging
679 depression in adolescence coincides with accelerated frontal cortical thinning. *J Child*
680 *Psychol Psychiatry* **59**, 994-1002, doi:10.1111/jcpp.12895 (2018).
- 681 15 Baum, G. L. *et al.* Development of structure-function coupling in human brain networks
682 during youth. *Proc Natl Acad Sci U S A* **117**, 771-778, doi:10.1073/pnas.1912034117
683 (2020).
- 684 16 Sakai, J. Core Concept: How synaptic pruning shapes neural wiring during development
685 and, possibly, in disease. *Proc Natl Acad Sci U S A* **117**, 16096-16099,
686 doi:10.1073/pnas.2010281117 (2020).
- 687 17 Hedman, A. M., van Haren, N. E., Schnack, H. G., Kahn, R. S. & Hulshoff Pol, H. E.
688 Human brain changes across the life span: a review of 56 longitudinal magnetic
689 resonance imaging studies. *Hum Brain Mapp* **33**, 1987-2002, doi:10.1002/hbm.21334
690 (2012).
- 691 18 Foulkes, L. & Blakemore, S. J. Studying individual differences in human adolescent
692 brain development. *Nat Neurosci* **21**, 315-323, doi:10.1038/s41593-018-0078-4 (2018).
- 693 19 Mills, K. L. *et al.* Inter-individual variability in structural brain development from late
694 childhood to young adulthood. *Neuroimage* **242**, 118450,
695 doi:10.1016/j.neuroimage.2021.118450 (2021).
- 696 20 Sisk, C. L. & Foster, D. L. The neural basis of puberty and adolescence. *Nat Neurosci* **7**,
697 1040-1047, doi:10.1038/nn1326 (2004).
- 698 21 Gogtay, N. *et al.* Dynamic mapping of human cortical development during childhood
699 through early adulthood. *Proc Natl Acad Sci U S A* **101**, 8174-8179,
700 doi:10.1073/pnas.0402680101 (2004).
- 701 22 Sowell, E. R. *et al.* Mapping cortical change across the human life span. *Nat Neurosci* **6**,
702 309-315, doi:10.1038/nn1008 (2003).
- 703 23 Noble, K. G. *et al.* Family income, parental education and brain structure in children and
704 adolescents. *Nat Neurosci* **18**, 773-778, doi:10.1038/nn.3983 (2015).
- 705 24 Rosenberg, M. D. *et al.* A neuromarker of sustained attention from whole-brain
706 functional connectivity. *Nat Neurosci* **19**, 165-171, doi:10.1038/nn.4179 (2016).
- 707 25 Mills, K. L. *et al.* Structural brain development between childhood and adulthood:
708 Convergence across four longitudinal samples. *Neuroimage* **141**, 273-281,
709 doi:10.1016/j.neuroimage.2016.07.044 (2016).
- 710 26 Brouwer, R. M. *et al.* Genetic variants associated with longitudinal changes in brain
711 structure across the lifespan. *Nat Neurosci* **25**, 421-432, doi:10.1038/s41593-022-01042-4
712 (2022).

- 713 27 Deary, I. J. *et al.* Genetic contributions to stability and change in intelligence from
714 childhood to old age. *Nature* **482**, 212-215, doi:10.1038/nature10781 (2012).
- 715 28 Bethlehem, R. A. I. *et al.* Brain charts for the human lifespan. *Nature* **604**, 525-533,
716 doi:10.1038/s41586-022-04554-y (2022).
- 717 29 Jack, C. R., Jr. *et al.* Tracking pathophysiological processes in Alzheimer's disease: an
718 updated hypothetical model of dynamic biomarkers. *Lancet Neurol* **12**, 207-216,
719 doi:10.1016/S1474-4422(12)70291-0 (2013).
- 720 30 Abi-Dargham, A. & Horga, G. The search for imaging biomarkers in psychiatric
721 disorders. *Nat Med* **22**, 1248-1255, doi:10.1038/nm.4190 (2016).
- 722 31 Schmaal, L. *et al.* Cortical abnormalities in adults and adolescents with major depression
723 based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive
724 Disorder Working Group. *Mol Psychiatry* **22**, 900-909, doi:10.1038/mp.2016.60 (2017).
- 725 32 Radua, J. *et al.* Ventral Striatal Activation During Reward Processing in Psychosis: A
726 Neurofunctional Meta-Analysis. *JAMA Psychiatry* **72**, 1243-1251,
727 doi:10.1001/jamapsychiatry.2015.2196 (2015).
- 728 33 Mayberg, H. S. *et al.* Reciprocal limbic-cortical function and negative mood: converging
729 PET findings in depression and normal sadness. *Am J Psychiatry* **156**, 675-682,
730 doi:10.1176/ajp.156.5.675 (1999).
- 731 34 Shafee, R., Buckner, R. L. & Fischl, B. Gray matter myelination of 1555 human brains
732 using partial volume corrected MRI images. *Neuroimage* **105**, 473-485,
733 doi:10.1016/j.neuroimage.2014.10.054 (2015).
- 734 35 Corrigan, N. M. *et al.* Myelin development in cerebral gray and white matter during
735 adolescence and late childhood. *Neuroimage* **227**, 117678,
736 doi:10.1016/j.neuroimage.2020.117678 (2021).
- 737 36 Zatorre, R. J., Fields, R. D. & Johansen-Berg, H. Plasticity in gray and white:
738 neuroimaging changes in brain structure during learning. *Nat Neurosci* **15**, 528-536,
739 doi:10.1038/nn.3045 (2012).
- 740 37 Schmidt, S. *et al.* Experience-dependent structural plasticity in the adult brain: How the
741 learning brain grows. *Neuroimage* **225**, 117502, doi:10.1016/j.neuroimage.2020.117502
742 (2021).
- 743 38 Whitaker, K. J. *et al.* Adolescence is associated with genomically patterned consolidation
744 of the hubs of the human brain connectome. *Proc Natl Acad Sci U S A* **113**, 9105-9110,
745 doi:10.1073/pnas.1601745113 (2016).
- 746 39 Mascarell Maricic, L. *et al.* The IMAGEN study: a decade of imaging genetics in
747 adolescents. *Mol Psychiatry* **25**, 2648-2671, doi:10.1038/s41380-020-0822-5 (2020).
- 748 40 Hori, T. *et al.* CCAN makes multiple contacts with centromeric DNA to provide distinct
749 pathways to the outer kinetochore. *Cell* **135**, 1039-1052, doi:10.1016/j.cell.2008.10.019
750 (2008).
- 751 41 Nishino, T. *et al.* CENP-T-W-S-X forms a unique centromeric chromatin structure with a
752 histone-like fold. *Cell* **148**, 487-501, doi:10.1016/j.cell.2011.11.061 (2012).
- 753 42 Aygun, N. *et al.* Brain-trait-associated variants impact cell-type-specific gene regulation
754 during neurogenesis. *Am J Hum Genet* **108**, 1647-1668, doi:10.1016/j.ajhg.2021.07.011
755 (2021).
- 756 43 Zhao, B. *et al.* Genome-wide association analysis of 19,629 individuals identifies variants
757 influencing regional brain volumes and refines their genetic co- architecture with

- 758 cognitive and mental health traits. *Nat Genet* **51**, 1637-1644, doi:10.1038/s41588-019-
759 0516-6 (2019).
- 760 44 Shin, J. *et al.* Global and Regional Development of the Human Cerebral Cortex:
761 Molecular Architecture and Occupational Aptitudes. *Cereb Cortex* **30**, 4121-4139,
762 doi:10.1093/cercor/bhaa035 (2020).
- 763 45 Grasby, K. L. *et al.* The genetic architecture of the human cerebral cortex. *Science* **367**,
764 doi:10.1126/science.aay6690 (2020).
- 765 46 Hofer, E. *et al.* Genetic correlations and genome-wide associations of cortical structure in
766 general population samples of 22,824 adults. *Nat Commun* **11**, 4796,
767 doi:10.1038/s41467-020-18367-y (2020).
- 768 47 van der Meer, D. *et al.* Understanding the genetic determinants of the brain with
769 MOSTest. *Nat Commun* **11**, 3512, doi:10.1038/s41467-020-17368-1 (2020).
- 770 48 van der Meer, D. *et al.* The genetic architecture of human cortical folding. *Sci Adv* **7**,
771 eabj9446, doi:10.1126/sciadv.abj9446 (2021).
- 772 49 Davies, G. *et al.* Study of 300,486 individuals identifies 148 independent genetic loci
773 influencing general cognitive function. *Nat Commun* **9**, 2098, doi:10.1038/s41467-018-
774 04362-x (2018).
- 775 50 Hill, W. D. *et al.* A combined analysis of genetically correlated traits identifies 187 loci
776 and a role for neurogenesis and myelination in intelligence. *Mol Psychiatry* **24**, 169-181,
777 doi:10.1038/s41380-017-0001-5 (2019).
- 778 51 Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association
779 study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112-1121,
780 doi:10.1038/s41588-018-0147-3 (2018).
- 781 52 Gudbjartsson, D. F. *et al.* Many sequence variants affecting diversity of adult human
782 height. *Nat Genet* **40**, 609-615, doi:10.1038/ng.122 (2008).
- 783 53 Berndt, S. I. *et al.* Genome-wide meta-analysis identifies 11 new loci for anthropometric
784 traits and provides insights into genetic architecture. *Nat Genet* **45**, 501-512,
785 doi:10.1038/ng.2606 (2013).
- 786 54 van der Valk, R. J. *et al.* A novel common variant in DCST2 is associated with length in
787 early life and height in adulthood. *Human molecular genetics* **24**, 1155-1168,
788 doi:10.1093/hmg/ddu510 (2015).
- 789 55 Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat
790 distribution. *Nature* **518**, 187-196, doi:10.1038/nature14132 (2015).
- 791 56 Tachmazidou, I. *et al.* Whole-Genome Sequencing Coupled to Imputation Discovers
792 Genetic Signals for Anthropometric Traits. *Am J Hum Genet* **100**, 865-884,
793 doi:10.1016/j.ajhg.2017.04.014 (2017).
- 794 57 Pearson, A. G., Curtis, M. A., Waldvogel, H. J., Faull, R. L. & Dragunow, M. Activating
795 transcription factor 2 expression in the adult human brain: association with both
796 neurodegeneration and neurogenesis. *Neuroscience* **133**, 437-451,
797 doi:10.1016/j.neuroscience.2005.02.029 (2005).
- 798 58 Suzuki, T., Yamakuni, T., Hagiwara, M. & Ichinose, H. Identification of ATF-2 as a
799 transcriptional regulator for the tyrosine hydroxylase gene. *J Biol Chem* **277**, 40768-
800 40774, doi:10.1074/jbc.M206043200 (2002).
- 801 59 Watson, G., Ronai, Z. A. & Lau, E. ATF2, a paradigm of the multifaceted regulation of
802 transcription factors in biology and disease. *Pharmacol Res* **119**, 347-357,
803 doi:10.1016/j.phrs.2017.02.004 (2017).

- 804 60 Islam, A., Mohammad, E. & Khan, M. A. Aberration of the modulatory functions of
805 intronic microRNA hsa-miR-933 on its host gene ATF2 results in type II diabetes
806 mellitus and neurodegenerative disease development. *Hum Genomics* **14**, 34,
807 doi:10.1186/s40246-020-00285-1 (2020).
- 808 61 Bellina, M. *et al.* Relationship between parenting measures and parents and child
809 psychopathological symptoms: a cross-sectional study. *BMC Psychiatry* **20**, 377,
810 doi:10.1186/s12888-020-02778-8 (2020).
- 811 62 Hagenaars, S. P. *et al.* Shared genetic aetiology between cognitive functions and physical
812 and mental health in UK Biobank (N=112 151) and 24 GWAS consortia. *Mol Psychiatry*
813 **21**, 1624-1632, doi:10.1038/mp.2015.225 (2016).
- 814 63 Hagenaars, S. P. *et al.* Genetic contributions to Trail Making Test performance in UK
815 Biobank. *Mol Psychiatry* **23**, 1575-1583, doi:10.1038/mp.2017.189 (2018).
- 816 64 Warriar, V. *et al.* Gene-environment correlations and causal effects of childhood
817 maltreatment on physical and mental health: a genetically informed approach. *Lancet*
818 *Psychiatry* **8**, 373-386, doi:10.1016/S2215-0366(20)30569-1 (2021).
- 819 65 Hughes, K. *et al.* The effect of multiple adverse childhood experiences on health: a
820 systematic review and meta-analysis. *Lancet Public Health* **2**, e356-e366,
821 doi:10.1016/S2468-2667(17)30118-4 (2017).
- 822 66 Sawyer, S. M. *et al.* Adolescence: a foundation for future health. *Lancet* **379**, 1630-1640,
823 doi:10.1016/S0140-6736(12)60072-5 (2012).
- 824 67 World Health, O. (World Health Organization, Geneva, 2001).
- 825 68 Worthman, C. M. & Trang, K. Dynamics of body time, social time and life history at
826 adolescence. *Nature* **554**, 451-457, doi:10.1038/nature25750 (2018).
- 827 69 Hensch, T. K. Critical period plasticity in local cortical circuits. *Nat Rev Neurosci* **6**, 877-
828 888, doi:10.1038/nrn1787 (2005).
- 829 70 Gopnik, A. *et al.* Changes in cognitive flexibility and hypothesis search across human life
830 history from childhood to adolescence to adulthood. *Proc Natl Acad Sci U S A* **114**, 7892-
831 7899, doi:10.1073/pnas.1700811114 (2017).
- 832 71 Drzewiecki, C. M., Willing, J. & Juraska, J. M. Synaptic number changes in the medial
833 prefrontal cortex across adolescence in male and female rats: A role for pubertal onset.
834 *Synapse* **70**, 361-368, doi:10.1002/syn.21909 (2016).
- 835 72 Petanjek, Z. *et al.* Extraordinary neoteny of synaptic spines in the human prefrontal
836 cortex. *Proc Natl Acad Sci U S A* **108**, 13281-13286, doi:10.1073/pnas.1105108108
837 (2011).
- 838 73 Zuo, Y., Lin, A., Chang, P. & Gan, W. B. Development of long-term dendritic spine
839 stability in diverse regions of cerebral cortex. *Neuron* **46**, 181-189,
840 doi:10.1016/j.neuron.2005.04.001 (2005).
- 841 74 Gogolla, N., Caroni, P., Luthi, A. & Herry, C. Perineuronal nets protect fear memories
842 from erasure. *Science* **325**, 1258-1261, doi:10.1126/science.1174146 (2009).
- 843 75 Davidow, J. Y., Foerde, K., Galvan, A. & Shohamy, D. An Upside to Reward Sensitivity:
844 The Hippocampus Supports Enhanced Reinforcement Learning in Adolescence. *Neuron*
845 **92**, 93-99, doi:10.1016/j.neuron.2016.08.031 (2016).
- 846 76 van den Bos, W., Cohen, M. X., Kahnt, T. & Crone, E. A. Striatum-medial prefrontal
847 cortex connectivity predicts developmental changes in reinforcement learning. *Cereb*
848 *Cortex* **22**, 1247-1255, doi:10.1093/cercor/bhr198 (2012).

- 849 77 Hauser, T. U., Iannaccone, R., Walitza, S., Brandeis, D. & Brem, S. Cognitive flexibility
850 in adolescence: neural and behavioral mechanisms of reward prediction error processing
851 in adaptive decision making during development. *Neuroimage* **104**, 347-354,
852 doi:10.1016/j.neuroimage.2014.09.018 (2015).
- 853 78 Ernst, M., Moolchan, E. T. & Robinson, M. L. Behavioral and neural consequences of
854 prenatal exposure to nicotine. *J Am Acad Child Adolesc Psychiatry* **40**, 630-641,
855 doi:10.1097/00004583-200106000-00007 (2001).
- 856 79 Bookstein, F. L., Streissguth, A. P., Sampson, P. D., Connor, P. D. & Barr, H. M. Corpus
857 callosum shape and neuropsychological deficits in adult males with heavy fetal alcohol
858 exposure. *Neuroimage* **15**, 233-251, doi:10.1006/nimg.2001.0977 (2002).
- 859 80 Sowell, E. R. *et al.* Abnormal cortical thickness and brain-behavior correlation patterns in
860 individuals with heavy prenatal alcohol exposure. *Cereb Cortex* **18**, 136-144,
861 doi:10.1093/cercor/bhm039 (2008).
- 862 81 Lees, B. *et al.* Association of Prenatal Alcohol Exposure With Psychological, Behavioral,
863 and Neurodevelopmental Outcomes in Children From the Adolescent Brain Cognitive
864 Development Study. *Am J Psychiatry* **177**, 1060-1072,
865 doi:10.1176/appi.ajp.2020.20010086 (2020).
- 866 82 Bublitz, M. H. & Stroud, L. R. Childhood sexual abuse is associated with cortisol
867 awakening response over pregnancy: preliminary findings. *Psychoneuroendocrinology* **37**,
868 1425-1430, doi:10.1016/j.psyneuen.2012.01.009 (2012).
- 869 83 Roussotte, F. F. *et al.* Regional brain volume reductions relate to facial dysmorphology
870 and neurocognitive function in fetal alcohol spectrum disorders. *Hum Brain Mapp* **33**,
871 920-937, doi:10.1002/hbm.21260 (2012).
- 872 84 Dazzan, P. & Murray, R. M. Neurological soft signs in first-episode psychosis: a
873 systematic review. *Br J Psychiatry Suppl* **43**, s50-57, doi:10.1192/bjp.181.43.s50 (2002).
- 874 85 Schroder, J. & Toro, P. Neurological soft signs predict outcomes in schizophrenia. *Nat*
875 *Rev Neurol* **16**, 659-660, doi:10.1038/s41582-020-0403-x (2020).
- 876 86 Seidl, U., Thomann, P. A. & Schroder, J. Neurological soft signs in nursing home
877 residents with Alzheimer's disease. *J Alzheimers Dis* **18**, 525-532, doi:10.3233/JAD-
878 2009-1159 (2009).
- 879 87 McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat*
880 *Genet* **48**, 1279-1283, doi:10.1038/ng.3643 (2016).
- 881 88 Luo, Q. *et al.* Association of a Schizophrenia-Risk Nonsynonymous Variant With
882 Putamen Volume in Adolescents: A Voxelwise and Genome-Wide Association Study.
883 *JAMA Psychiatry* **76**, 435-445, doi:10.1001/jamapsychiatry.2018.4126 (2019).
- 884 89 International HapMap, C. *et al.* Integrating common and rare genetic variation in diverse
885 human populations. *Nature* **467**, 52-58, doi:10.1038/nature09298 (2010).
- 886 90 Demontis, D. *et al.* Discovery of the first genome-wide significant risk loci for attention
887 deficit/hyperactivity disorder. *Nat Genet* **51**, 63-75, doi:10.1038/s41588-018-0269-7
888 (2019).
- 889 91 Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum
890 disorder. *Nat Genet* **51**, 431-444, doi:10.1038/s41588-019-0344-8 (2019).
- 891 92 Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals
892 identifies new genetic and functional links to intelligence. *Nat Genet* **50**, 912-919,
893 doi:10.1038/s41588-018-0152-6 (2018).
- 894


895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926

Acknowledgments and funding: This work received support from the following sources:
National Key R&D Program of China (No.2019YFA0709502), National Key R&D Program of
China (No.2018YFC1312904), Shanghai Municipal Science and Technology Major Project
(No.2018SHZDZX01), ZJ Lab, and Shanghai Center for Brain Science and Brain-Inspired
Technology, the 111 Project (No.B18015), the European Union-funded FP6 Integrated Project
IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology)
(LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant ‘STRATIFY’
(Brain network based stratification of reinforcement-related disorders) (695313), Human Brain
Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the Medical Research Council Grant
'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions)
(MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro
and micro gene-by-environment interaction analysis of substance use behavior and its brain
biomarkers), the National Institute for Health Research (NIHR) Biomedical Research Centre at
South London and Maudsley NHS Foundation Trust and King’s College London, the
Bundesministerium für Bildung und Forschung (BMBF grants 01GS08152; 01EV0711;
Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B),
the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE
1383/14-1), the Medical Research Foundation and Medical Research Council (grants
MR/R00465X/1 and MR/S020306/1), the National Institutes of Health (NIH) funded ENIGMA
(grants 5U54EB020403-05 and 1R56AG058854-01), NSFC grant 82150710554 and
environMENTAL grant. Further support was provided by grants from: - the ANR (ANR-12-
SAMA-0004, AAPG2019 - GeBra), the Eranet Neuron (AF12-NEUR0008-01 - WM2NA; and
ANR-18-NEUR00002-01 - ADORe), the Fondation de France (00081242), the Fondation pour la
Recherche Médicale (DPA20140629802), the Mission Interministérielle de Lutte-contre-les-
Drogues-et-les-Conduites-Addictives (MILDECA), the Assistance-Publique-Hôpitaux-de-Paris
and INSERM (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir
(grant AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the National Institutes
of Health, Science Foundation Ireland (16/ERCD/3797), U.S.A. (Axon, Testosterone and Mental


927 Health during Adolescence; RO1 MH085772-01A1) and by NIH Consortium grant U54
928 EB020403, supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of
929 Excellence. The funders had no role in study design, data collection and analysis, decision to
930 publish or preparation of the manuscript.

931 **Competing Interests:** Dr Banaschewski served in an advisory or consultancy role for Lundbeck,
932 Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or
933 speaker's fee by Lilly, Medice, Novartis and Shire. He has been involved in clinical trials
934 conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP
935 Medien, Oxford University Press. The present work is unrelated to the above grants and
936 relationships. Dr Barker receives honoraria for teaching from GE Healthcare. Dr Poustka served
937 in an advisory or consultancy role for Roche and Viforpharm and received speaker's fee by Shire.
938 She received royalties from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated
939 to the above grants and relationships. The other authors report no biomedical financial interests
940 or potential conflicts of interest.


a IMAGEN longitudinal study: n=1,543



c



b



d




Fig. 1 Whole-brain gray matter volume (GMV) developmental patterns define three neurodevelopmental groups.

(a) Schematic workflow of data sets and analytic methodologies. GMV trajectory in 44 ROIs spanning the cortical and subcortical areas was estimated using linear mixed effect models for adolescents in the IMAGEN study ($n=1,543$). Principal component analysis and multivariate clustering were conducted to identify groups with distinct neurodevelopmental patterns. Next, groups were characterized in terms of neurocognition and risk factors for neuropsychiatric disorders. Genome-wide association study (GWAS) was conducted in the ABCD study ($n=7,662$) using group-reweighted GMV as the proxy phenotype for delayed neurodevelopment, and results were further validated in IMAGEN. Epigenome-wide association study (EWAS) was conducted in IMAGEN ($n=909$) to identify potential environmental exposures associated with neurodevelopment. Last, long-term impacts of the polygenic risk for delayed neurodevelopment on multiple outcomes were investigated among participants in UK Biobank ($n=502,486$) (**Methods**). BL, baseline; FU1, follow-up 1 at 16 y; FU2, follow-up 1 at 19 y; FU3, follow-up 1 at 23 y. **(b)** Whole-brain GMV growth rates (ranging from increase, stable to decrease) at age 5y, 10y, 15y, 20y and 25y were estimated for each group identified in IMAGEN, adjusting for sex, imaging site, handedness and intra-cranial volume (**Methods**). Group 3 showed delayed GMV development compared to Group 1 and 2. **(c)** Total GMV developmental trajectories (with 95% confidence bands) for the three groups identified in the IMAGEN study (Group 1-3). These trajectories were estimated adjusting for sex, imaging site, handedness and intra-cranial volume (**Methods**). Group 1 and 2 exhibited similar GMV developmental trend, while Group 3 had opposite GMV developmental trend. **(d)** The top 5 discriminating ROIs with largest t values comparing the GMV trajectories between Group 3 ($n=67$) and Group 1 ($n=711$) (top), and between Group 2 ($n=765$) and Group 1 ($n=711$) (bottom), adjusting for sex, imaging site, handedness and intra-cranial volume. Two sample t -test: Group 3 vs Group 1, IFT ($d=4.43$, $t=20.13$, $***P_{adj}<0.001$), MT ($d=4.38$, $t=20.07$, $***P_{adj}<0.001$), LatOFC ($d=4.26$, $t=18.31$, $***P_{adj}<0.001$), PreC ($d=3.63$, $t=18.11$, $***P_{adj}<0.001$), SF ($d=3.61$, $t=17.92$, $***P_{adj}<0.001$); Group 2 vs Group 1, SF ($d=1.28$, $t=24.50$, $***P_{adj}<0.001$), RMF ($d=1.14$, $t=21.95$, $***P_{adj}<0.001$), CMF ($d=1.09$, $t=20.77$, $***P_{adj}<0.001$), PreC ($d=1.05$, $t=20.14$, $***P_{adj}<0.001$), IFP ($d=1.00$, $t=19.07$, $***P_{adj}<0.001$). LatOFC, lateral orbitofrontal cortex; RMF, rostral middle frontal; CMF, caudal middle frontal; SF, superior frontal; PreC, precentral; MT, middle temporal; IFT, inferior temporal; IFP, inferior parietal.




Fig. 2 Structural neurodevelopment predicts neurocognition and risk factors for neuropsychiatric disorders.

(a) Comparison of neurocognitive performances between Group 3 and Group 1 (orange), and between Group 2 and Group 1 (green) at baseline (BL) and the last follow-up (FU) (**Methods**). Total number of neurocognitive tests in cantab where Group 3 performed worse than Group 1 decreased from 7/12 at baseline to 1/12 at follow-up 3, while the number of tests where Group 2 performed worse than Group 1 increased from 0 to 3/12. Full results with item-specific comparisons among these groups are provided in **Supplementary Fig. 7**. CANTAB, Cambridge Neuropsychological Test Automated Battery. **(b)** Longitudinal trajectories of Depression (Left) and ADHD symptoms (Right) among adolescents in the three groups. Group-specific means at each visit were plotted and * indicated significant differences relative to Group 1 adjusting for sex, handedness, stie and ICV. Baseline mental health score was also adjusted for comparison at the last follow-up. Statistical tests were conducted at baseline (14y) and the last follow-up. Depression, Group 2 vs Group 1 at 14y ($d=-0.05$, $P=0.256$), Group 2 vs Group 1 at 23y ($d=0.13$, $*P=0.023$), Group 3 vs Group 1 at 14y ($d=-0.01$, $P=0.566$), Group 3 vs Group 1 at 23y ($d=0.70$, $**P=0.001$); Parent rated ADHD, Group 2 vs Group 1 at 14y ($d=0.04$, $P=0.220$), Group 2 vs Group 1 at 16y ($d=-0.03$, $P=0.574$), Group 3 vs Group 1 at 14y ($d=0.34$, $**P=0.004$), Group 3 vs Group 1 at 16y ($d=0.01$, $P=0.954$); Child rated ADHD, Group 2 vs Group 1 at 14y ($d=-0.03$, $P=0.321$), Group 2 vs Group 1 at 23y ($d=0.02$, $P=0.758$), Group 3 vs Group 1 at 14y ($d=0.34$, $P=0.042$), Group 3 vs Group 1 at 23y ($d=-0.10$, $P=0.579$). ADHD, attention-deficit/hyperactivity disorder.




Fig. 3 Genome-wide association study (GWAS) identified two significant loci associated with delayed neurodevelopment in Group 3.

(a) Correlation between Group3-reweighted GMV and neurocognition (**Supplementary Methods**) in ABCD ($n=11,101$) indicated the validity of using the proxy phenotype for delayed neurodevelopment in the following GWAS. GDT, Game of Dice Task; DDT, Dealy Discounting Task; PVT, Picture Vocabulary Test; Flanker, Flanker Inhibitory Control and Attention Test; List, List Sorting Working Memory Test; DCCS, Dimensional Change Card Sort Test; Pattern, Pattern Comparison Processing Speed Test; PSMT, Picture Sequence Memory Test; Reading, Oral Reading Recognition Test; FluidCog, fluid cognition; CrystalCog, crystallized cognition; TotalCog, total cognition. *** $P < 0.001$; ** $P < 0.01$; * $P < 0.05$. **(b)** GWAS Manhattan plot for Group3-reweighted GMV in the ABCD population ($n=7,662$). Group3-reweighted GMV was calculated for each adolescent (**Methods**) and used as the proxy phenotype for delayed neurodevelopment. Multiple SNPs on chromosome 6 achieved genome-wide significant effects ($P < 5 \times 10^{-8}$). SNPs on chromosome 6 were mapped to the intronic region of *CENPW*. Results from gene based association analysis (**Supplementary Fig. 11**) confirmed the significant effect of *CENPW* on delayed neurodevelopment. Box plot in **(c)** showed that *CENPW* score of delayed neurodevelopment was higher in Group 3 ($n=60$) compared to Group 1 and 2 ($n=1,338$) (two-sided t-test: $P=0.028$). **(d)** indicated that *CENPW* score of delayed neurodevelopment was negatively correlated with baseline (BL) neurocognitive performance, and became non-significant at the last follow-up (FU). Here, *Worse* indicated higher CGT Delay aversion score, lower CGT risk adjustment score, longer CGT Deliberation time and SST GoRT. CGT Delay aversion, BL ($r=0.09$, $*P_{adj}=0.027$), FU3 ($r=0.07$, $P_{adj}=0.239$); CGT Deliberation time, BL ($r=0.08$, $*P_{adj}=0.027$), FU3 ($r=-0.02$, $P_{adj}=0.983$); CGT risk adjustment, BL ($r=-0.08$, $*P_{adj}=0.027$), FU3 ($r=0.022$, $P_{adj}=0.983$); SST GoRT, BL ($r=-0.06$, $*P_{adj}=0.038$), FU3 ($r=-0.03$, $P_{adj}=0.472$). CGT, Cambridge Gambling Task; SST GoRT, reaction time for 'Go' trials in Stop Signal Task. **(c-d)** confirmed the relationship between *CENPW* and delayed neurodevelopment identified in **(b)**.




Fig. 4 Epigenome-wide association study (EWAS) identified significant signals associated with lowered neurodevelopment in Group 2.

(a) EWAS Manhattan plot in the IMAGEN population. Group 2 ($n=463$) (relative to Group 1, $n=446$) status was used as the phenotype, adjusting for potential confounders (Methods). One hypermethylated site cg06064461 achieved genome-wide significant effect ($P < 5 \times 10^{-8}$, $P_{adj} < 0.05$) and was mapped to *ATF2* and *MIR933* on chromosome 2. (b-c) Validation of EWAS results in IMAGEN ($n=909$). cg06064461 methylation was positively correlated with total GMV trajectory (b; $r=0.14$, $***P < 0.001$) and negatively correlated with peak gray matter volume (GMV) (c; $r=-0.07$, $*P=0.020$), adjusting for potential confounders (Methods). (d) Proportion of the mediation effects through cg06064461 methylation in the environmental exposure - peak GMV pathway, adjusting for potential confounders. Environmental factors were sorted by P values of the mediation effects. Although none mediation effects of cg06064461 methylation showed statistical significance after correcting for multiple testing, nominal significance was observed between family affirmation and peak GMV. Childexp, child's experience of family life; FamStress, family stressors; CTQ, Childhood Trauma Questionnaire. (e) Mediation model was conducted to analyze the direct and indirect effect of family affirmation on peak GMV, with cg06064461 methylation as the mediator. Results showed that cg06064461 methylation significantly mediate the relationship between family affirmation and peak GMV ($\beta=0.005$, $*P=0.048$).




Fig. 5 Genetically-predicted neurodevelopment had limited impact on socio-economic, cognitive and mental health outcomes in mid-to-late adulthood.

(a) Correlation between polygenic risk score (PRS) of delayed neurodevelopment and total gray matter volume (GMV) for participants in UK Biobank ($n=337,199$). Marginal distributions of PRS and total GMV were both normal. PRS and CENPW score both showed negative correlation with total GMV ($r=-0.07$, $***P<0.001$ for PRS and $r=-0.07$, $***P<0.001$ for CENPW score). PRS were averaged over different P value thresholds. (b) Correlation between averaged PRS of delayed neurodevelopment and CENPW score and regional GMV for participants in UK Biobank. Inferior temporal ($r=-0.07$, $***P_{adj}<0.001$), fusiform ($r=-0.06$, $***P_{adj}<0.001$), middle temporal ($r=-0.06$, $***P_{adj}<0.001$), medialorbitofrontal ($r=-0.06$, $***P_{adj}<0.001$) and lateralorbitofrontal ($r=-0.06$, $***P_{adj}<0.001$) were among the ROIs with the strongest correlation with PRS, while lateralorbitofrontal ($r=-0.06$, $***P_{adj}<0.001$), caudalmiddlefrontal ($r=-0.05$, $***P_{adj}<0.001$), rostralmiddlefrontal ($r=-0.05$, $***P_{adj}<0.001$), insula ($r=-0.05$, $***P_{adj}<0.001$) and superiorfrontal ($r=-0.05$, $***P_{adj}<0.001$) were ROIs having the strongest correlation with CENPW score. These were consistent with the results that participants with higher PRS of delayed neurodevelopment also had worse performance in spatial working memory in UK Biobank. (c) Inferiority test of the correlation between averaged PRS and socio-economic, cognitive and mental health outcomes (**Supplementary Methods**) indicated that polygenic risk of delayed neurodevelopment had limited effect on the long-term socio-economic, cognitive and mental health outcomes. Full results were displayed in **Supplementary Fig. 14**. Similar results were observed between CENPW score and these long-term outcomes (**Supplementary Fig. 15**). IMD, Indices of Multiple Deprivation; Scot, Scotland; Edu, the highest educational level; IQ, intelligence.